Cencora Set to Announce Q1 Earnings on February 4th
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2h ago
0mins
Should l Buy COR?
Source: seekingalpha
- Earnings Announcement: Cencora (COR) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimates at $4.04, reflecting an 8.3% year-over-year growth, which could further solidify its growth position in the industry.
- Revenue Expectations: The revenue is projected to reach $86.17 billion, marking a 5.7% year-over-year increase, indicating the company's ongoing expansion in the high-growth specialty services sector, potentially attracting more investor interest.
- Historical Performance: Over the past two years, Cencora has achieved a 100% accuracy rate in EPS estimates and a 75% accuracy rate in revenue estimates, showcasing its strong forecasting capabilities and bolstering market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates experienced two upward and three downward revisions, reflecting mixed market sentiment regarding Cencora's future performance, which may influence investor decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy COR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on COR
Wall Street analysts forecast COR stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COR is 394.00 USD with a low forecast of 360.00 USD and a high forecast of 417.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 363.560
Low
360.00
Averages
394.00
High
417.00
Current: 363.560
Low
360.00
Averages
394.00
High
417.00
About COR
Cencora, Inc. is a global pharmaceutical sourcing and distribution services company. The Company helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The Company operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cencora Set to Announce Q1 Earnings on February 4th
- Earnings Announcement: Cencora (COR) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimates at $4.04, reflecting an 8.3% year-over-year growth, which could further solidify its growth position in the industry.
- Revenue Expectations: The revenue is projected to reach $86.17 billion, marking a 5.7% year-over-year increase, indicating the company's ongoing expansion in the high-growth specialty services sector, potentially attracting more investor interest.
- Historical Performance: Over the past two years, Cencora has achieved a 100% accuracy rate in EPS estimates and a 75% accuracy rate in revenue estimates, showcasing its strong forecasting capabilities and bolstering market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates experienced two upward and three downward revisions, reflecting mixed market sentiment regarding Cencora's future performance, which may influence investor decisions.
See More
Covetrus in Talks to Acquire Cencora's Veterinary Business
- Acquisition Talks Initiated: Covetrus is in preliminary discussions to acquire Cencora's veterinary business, a move that could further solidify Covetrus's position in the veterinary tech market and enhance its market share.
- Financing Arrangements: Covetrus's owners, CD&R and TPG, are negotiating with private credit firms like Blue Owl Capital to secure approximately $3 billion in new debt, aimed at refinancing Covetrus's existing $2 billion debt and supporting the potential acquisition.
- Privatization Background: CD&R and TPG took Covetrus private in 2022 in a deal valued at about $4 billion, and this acquisition negotiation reflects their ongoing commitment to investing in the veterinary market, potentially laying the groundwork for future growth.
- Market Reaction: Although CD&R, TPG, Cencora, and Blue Owl declined to comment, the market holds a cautiously optimistic view on Covetrus's acquisition plans, believing it will enhance its financial stability and competitive edge.
See More
Key Highlights to Monitor This Week: Jobs Report, Amazon, Disney, Alphabet, Palantir, and More
Market Volatility: Last week saw increased volatility in equities, with the S&P 500 ending slightly up and the Nasdaq Composite slightly down after a steady interest rate announcement by the Federal Open Market Committee.
Microsoft's Earnings Impact: Microsoft experienced a significant drop of 10% in its stock value, resulting in a loss of $357 billion in market capitalization following a disappointing earnings report.
Silver Market Collapse: The silver market faced a dramatic decline, falling 31% in a single day, attributed to the nomination of hawkish Kevin Warsh as the next Fed Chair and a prior 50% increase in value this year.
Overall Economic Sentiment: The combination of these events reflects a turbulent economic sentiment, with investors reacting to both corporate earnings and shifts in monetary policy.
See More
Morgan Stanley Upgrades Cencora and Raises Price Targets for Rivals
- Rating Upgrade: Morgan Stanley upgraded Cencora (COR) from Equal Weight to Overweight and raised its price target from $361 to $400, reflecting the company's leadership in specialty pharmaceuticals and efforts to optimize its business portfolio.
- Market Consolidation: By acquiring a majority stake in OneOncology, Cencora is expected to solidify its market-leading position in specialty pharmaceuticals, with international expansion potentially accelerating in FY26 supported by its World Courier division.
- Industry Outlook: The analyst also raised price targets for McKesson (MCK) and Cardinal Health (CAH) to $966 and $245 respectively, indicating that despite outperforming the S&P 500 last year, the drug distribution industry is expected to continue thriving in 2026.
- Strategic Optimization: Cencora is weighing strategic alternatives for its non-core assets, which the analyst identifies as a key step in optimizing its business portfolio, suggesting that this move should be rewarded by the market.
See More
Cigna Corp Analysts Upgrade to 51% Upside, Healthcare Stocks Show Strong Growth
- Cigna's Strong Performance: Cigna Corp (NYSE:CI) leads with a 51.0% analyst upside and a remarkable 145.5% EPS growth forecast, showcasing its strong performance as a 'cash flow machine' that remains undervalued, poised for significant shareholder returns.
- Regeneron's Innovation Strength: Regeneron Pharmaceuticals Inc (F:REGN) ranks second with a 26.0% analyst upside and 21.5% projected EPS growth, recognized for its high-margin innovation in the biopharmaceutical sector, supporting its optimistic future growth prospects and industry leadership.
- Cencora's Distribution Edge: Cencora Inc (NYSE:COR), formerly AmerisourceBergen, secures third place with a 23.1% analyst upside and an impressive 120.0% EPS growth forecast, leveraging its extensive distribution network and strategic positioning in healthcare logistics for significant competitive advantages.
- Merck's Stable Growth: Merck & Company Inc (NYSE:MRK) rounds out the list with a 21.2% analyst upside potential and 34.2% projected EPS growth, described as a 'defensive pharma leader' that offers stability alongside growth potential through its diverse pharmaceutical portfolio, providing multiple revenue streams to mitigate market volatility.
See More
Cencora Elects Ellen Cooper as Independent Director Effective January 20, 2026
- New Board Member: Cencora has appointed Ellen Cooper as an independent director, effective January 20, 2026, aiming to enhance the board's expertise to support the company's sustainable growth.
- Industry Leader Background: Ellen Cooper brings extensive experience from the insurance sector, having served as CEO of Lincoln Financial, where she gained expertise in risk management and investment, expected to provide strategic guidance to Cencora.
- Education and Credentials: Cooper holds a Bachelor of Business Administration from Temple University and possesses multiple professional qualifications, including Fellow of the Society of Actuaries and Chartered Financial Analyst, further enhancing her value on the board.
- Alignment with Company Vision: Cencora's CEO Robert P. Mauch stated that Cooper's appointment will help strengthen the company's leadership position in global pharmaceutical solutions and advance its mission of creating healthier futures.
See More
Cencora Set to Announce Q1 Earnings on February 4th
- Earnings Announcement: Cencora (COR) is set to release its Q1 2023 earnings on February 4th before market open, with consensus EPS estimates at $4.04, reflecting an 8.3% year-over-year growth, which could further solidify its growth position in the industry.
- Revenue Expectations: The revenue is projected to reach $86.17 billion, marking a 5.7% year-over-year increase, indicating the company's ongoing expansion in the high-growth specialty services sector, potentially attracting more investor interest.
- Historical Performance: Over the past two years, Cencora has achieved a 100% accuracy rate in EPS estimates and a 75% accuracy rate in revenue estimates, showcasing its strong forecasting capabilities and bolstering market confidence in its future performance.
- Estimate Revision Dynamics: In the last three months, EPS estimates have seen three upward revisions and four downward adjustments, while revenue estimates experienced two upward and three downward revisions, reflecting mixed market sentiment regarding Cencora's future performance, which may influence investor decisions.
See More
Covetrus in Talks to Acquire Cencora's Veterinary Business
- Acquisition Talks Initiated: Covetrus is in preliminary discussions to acquire Cencora's veterinary business, a move that could further solidify Covetrus's position in the veterinary tech market and enhance its market share.
- Financing Arrangements: Covetrus's owners, CD&R and TPG, are negotiating with private credit firms like Blue Owl Capital to secure approximately $3 billion in new debt, aimed at refinancing Covetrus's existing $2 billion debt and supporting the potential acquisition.
- Privatization Background: CD&R and TPG took Covetrus private in 2022 in a deal valued at about $4 billion, and this acquisition negotiation reflects their ongoing commitment to investing in the veterinary market, potentially laying the groundwork for future growth.
- Market Reaction: Although CD&R, TPG, Cencora, and Blue Owl declined to comment, the market holds a cautiously optimistic view on Covetrus's acquisition plans, believing it will enhance its financial stability and competitive edge.
See More
Key Highlights to Monitor This Week: Jobs Report, Amazon, Disney, Alphabet, Palantir, and More
Market Volatility: Last week saw increased volatility in equities, with the S&P 500 ending slightly up and the Nasdaq Composite slightly down after a steady interest rate announcement by the Federal Open Market Committee.
Microsoft's Earnings Impact: Microsoft experienced a significant drop of 10% in its stock value, resulting in a loss of $357 billion in market capitalization following a disappointing earnings report.
Silver Market Collapse: The silver market faced a dramatic decline, falling 31% in a single day, attributed to the nomination of hawkish Kevin Warsh as the next Fed Chair and a prior 50% increase in value this year.
Overall Economic Sentiment: The combination of these events reflects a turbulent economic sentiment, with investors reacting to both corporate earnings and shifts in monetary policy.
See More
Morgan Stanley Upgrades Cencora and Raises Price Targets for Rivals
- Rating Upgrade: Morgan Stanley upgraded Cencora (COR) from Equal Weight to Overweight and raised its price target from $361 to $400, reflecting the company's leadership in specialty pharmaceuticals and efforts to optimize its business portfolio.
- Market Consolidation: By acquiring a majority stake in OneOncology, Cencora is expected to solidify its market-leading position in specialty pharmaceuticals, with international expansion potentially accelerating in FY26 supported by its World Courier division.
- Industry Outlook: The analyst also raised price targets for McKesson (MCK) and Cardinal Health (CAH) to $966 and $245 respectively, indicating that despite outperforming the S&P 500 last year, the drug distribution industry is expected to continue thriving in 2026.
- Strategic Optimization: Cencora is weighing strategic alternatives for its non-core assets, which the analyst identifies as a key step in optimizing its business portfolio, suggesting that this move should be rewarded by the market.
See More
Cigna Corp Analysts Upgrade to 51% Upside, Healthcare Stocks Show Strong Growth
- Cigna's Strong Performance: Cigna Corp (NYSE:CI) leads with a 51.0% analyst upside and a remarkable 145.5% EPS growth forecast, showcasing its strong performance as a 'cash flow machine' that remains undervalued, poised for significant shareholder returns.
- Regeneron's Innovation Strength: Regeneron Pharmaceuticals Inc (F:REGN) ranks second with a 26.0% analyst upside and 21.5% projected EPS growth, recognized for its high-margin innovation in the biopharmaceutical sector, supporting its optimistic future growth prospects and industry leadership.
- Cencora's Distribution Edge: Cencora Inc (NYSE:COR), formerly AmerisourceBergen, secures third place with a 23.1% analyst upside and an impressive 120.0% EPS growth forecast, leveraging its extensive distribution network and strategic positioning in healthcare logistics for significant competitive advantages.
- Merck's Stable Growth: Merck & Company Inc (NYSE:MRK) rounds out the list with a 21.2% analyst upside potential and 34.2% projected EPS growth, described as a 'defensive pharma leader' that offers stability alongside growth potential through its diverse pharmaceutical portfolio, providing multiple revenue streams to mitigate market volatility.
See More
Cencora Elects Ellen Cooper as Independent Director Effective January 20, 2026
- New Board Member: Cencora has appointed Ellen Cooper as an independent director, effective January 20, 2026, aiming to enhance the board's expertise to support the company's sustainable growth.
- Industry Leader Background: Ellen Cooper brings extensive experience from the insurance sector, having served as CEO of Lincoln Financial, where she gained expertise in risk management and investment, expected to provide strategic guidance to Cencora.
- Education and Credentials: Cooper holds a Bachelor of Business Administration from Temple University and possesses multiple professional qualifications, including Fellow of the Society of Actuaries and Chartered Financial Analyst, further enhancing her value on the board.
- Alignment with Company Vision: Cencora's CEO Robert P. Mauch stated that Cooper's appointment will help strengthen the company's leadership position in global pharmaceutical solutions and advance its mission of creating healthier futures.
See More
